Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool.
Cancer
PI3Kγ
drug discovery
flavonoids
flavopiridol
kinase
small molecules
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
06
2023
accepted:
04
10
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Cancer has been one of the leading causes of mortality worldwide over the past few years. Some progress has been made in the development of more effective cancer therapeutics, resulting in improved survival rates. However, the desired outcome in the form of successful treatment is yet to be achieved. There is high demand for the development of innovative, inexpensive, and effective anticancer treatments using natural resources. Natural compounds have been increasingly discovered and used for cancer therapy owing to their high molecular diversity, novel biofunctionality, and minimal side effects. These compounds can be utilized as chemopreventive agents because they can efficiently inhibit cell growth, control cell cycle progression, and block several tumor-promoting signaling pathways. PI3K is an important upstream protein of the PI3K-Akt-mTOR pathway and a well-established cancer therapeutic target. This study aimed to explore the small molecules, natural flavonoids, viz. quercetin, luteolin, kaempferol, genistein, wogonin, daidzein, and flavopiridol for PI3Kγ kinase activity inhibition. In this study, the binding pose, interacting residues, molecular interactions, binding energies, and dissociation constants were investigated. Our results showed that these flavonoids bound well with PI3Kγ with adequate binding strength scores and binding energy ranging from (-8.19 to -8.97 Kcal/mol). Among the explored ligands, flavopiridol showed the highest binding energy of -8.97 Kcal/mol, dock score (-44.40), and dissociation constant term,
Identifiants
pubmed: 37900167
doi: 10.3389/fphar.2023.1236173
pii: 1236173
pmc: PMC10612336
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1236173Informations de copyright
Copyright © 2023 Suhail, AlZahrani, Shakil, Tarique, Tabrez, Zughaibi and Rehan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Life Sci. 2019 Dec 15;239:117073
pubmed: 31751581
PLoS One. 2014 Feb 27;9(2):e87309
pubmed: 24586269
Int J Mol Sci. 2023 May 11;24(10):
pubmed: 37239974
Curr Opin Chem Biol. 2019 Jun;50:111-119
pubmed: 31004963
Sci Transl Med. 2010 Sep 8;2(48):48ps45
pubmed: 20826838
Front Nutr. 2023 Jan 11;9:1078642
pubmed: 36712528
Onco Targets Ther. 2017 Jun 06;10:2865-2871
pubmed: 28652768
Antioxidants (Basel). 2021 Jul 19;10(7):
pubmed: 34356371
Cancer Treat Rev. 2009 Feb;35(1):57-68
pubmed: 19004559
J Cell Mol Med. 2023 Oct;27(20):3168-3188
pubmed: 37724615
Heliyon. 2019 May 09;5(5):e01675
pubmed: 31193061
Int J Mol Sci. 2019 May 16;20(10):
pubmed: 31100782
PLoS One. 2019 Jun 27;14(6):e0219180
pubmed: 31247018
Int J Biol Sci. 2022 May 16;18(9):3636-3652
pubmed: 35813479
Inflammopharmacology. 2021 Oct;29(5):1587-1601
pubmed: 34322786
Curr Med Chem. 2021;28(21):4117-4132
pubmed: 33176636
Cancers (Basel). 2021 Jun 04;13(11):
pubmed: 34200019
Curr Issues Mol Biol. 2021 Oct 10;43(3):1502-1517
pubmed: 34698063
Curr Med Chem. 2021;28(39):8083-8097
pubmed: 34348607
Evid Based Complement Alternat Med. 2021 Jun 15;2021:9935451
pubmed: 34221094
Cells. 2022 Jul 15;11(14):
pubmed: 35883653
Food Funct. 2023 Jan 23;14(2):934-945
pubmed: 36541083
J Med Virol. 2023 Aug;95(8):e28981
pubmed: 37515471
Int J Mol Sci. 2023 May 16;24(10):
pubmed: 37240168
Biomed Pharmacother. 2019 Aug;116:109004
pubmed: 31128404
Int J Mol Sci. 2023 Feb 23;24(5):
pubmed: 36901876
PLoS One. 2022 Feb 25;17(2):e0263853
pubmed: 35213606
Nat Commun. 2016 Jun 20;7:11971
pubmed: 27321283
Pharmaceuticals (Basel). 2012 Nov 20;5(11):1236-64
pubmed: 24281308
Cancer Cell Int. 2022 Dec 8;22(1):386
pubmed: 36482329
Semin Cancer Biol. 2019 Dec;59:125-132
pubmed: 31323288
Cancer Cell Int. 2022 Aug 15;22(1):257
pubmed: 35971151
Oncol Res. 2019 Jun 21;27(6):629-634
pubmed: 29739490
Molecules. 2021 Sep 04;26(17):
pubmed: 34500810
Anticancer Agents Med Chem. 2013 Sep;13(7):1014-24
pubmed: 23272911
CA Cancer J Clin. 2022 Sep;72(5):409-436
pubmed: 35736631
Nutrients. 2016 Aug 29;8(9):
pubmed: 27589790
Int J Mol Sci. 2021 Nov 18;22(22):
pubmed: 34830339
Anticancer Res. 2020 Aug;40(8):4547-4556
pubmed: 32727785
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Cell Chem Biol. 2020 Aug 20;27(8):998-1014
pubmed: 32795419
Front Pharmacol. 2021 Apr 15;12:663551
pubmed: 33935785
J Comput Aided Mol Des. 2001 May;15(5):411-28
pubmed: 11394736
Curr Cancer Drug Targets. 2009 Mar;9(2):237-49
pubmed: 19275762